Literature DB >> 17584079

Congenital Disorders of Glycosylation: CDG-I, CDG-II, and beyond.

Hudson H Freeze1.   

Abstract

The Congenital Disorders of Glycosylation (CDG) are a collection of over 20 inherited diseases that impair protein N-glycosylation. The clinical appearance of CDG patients is quite diverse making it difficult for physicians to recognize them. A simple blood test of transferrin glycosylation status signals a glycosylation abnormality, but not the specific defect. An abnormal trasferrin glycosylation pattern suggests that the defect is in either genes that synthesize and add the precursor glycan (Glc(3)Man(9)GlcNAc(2)) to proteins (Type I) or genes that process the protein-bound N-glycans (Type II). Type I defects create unoccupied glycosylation sites, while Type II defects give fully occupied sites with abnormally processed glycans. These types are expected to be mutually exclusive, but a group of patients is now emerging who have variable coagulopathy and hypoglycemia together with a combination of Type I and Type II transferrin features. This surprising finding makes identifying their defects more challenging, but the defects and associated clinical manifestations of these patients suggest that the N-glycosylation pathway has some secrets left to share.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17584079     DOI: 10.2174/156652407780831548

Source DB:  PubMed          Journal:  Curr Mol Med        ISSN: 1566-5240            Impact factor:   2.222


  43 in total

1.  Neurology of inherited glycosylation disorders.

Authors:  Hudson H Freeze; Erik A Eklund; Bobby G Ng; Marc C Patterson
Journal:  Lancet Neurol       Date:  2012-05       Impact factor: 44.182

Review 2.  Vertebrate protein glycosylation: diversity, synthesis and function.

Authors:  Kelley W Moremen; Michael Tiemeyer; Alison V Nairn
Journal:  Nat Rev Mol Cell Biol       Date:  2012-06-22       Impact factor: 94.444

Review 3.  Role of the conserved oligomeric Golgi (COG) complex in protein glycosylation.

Authors:  Richard D Smith; Vladimir V Lupashin
Journal:  Carbohydr Res       Date:  2008-02-02       Impact factor: 2.104

Review 4.  Long-standing mild hypertransaminasaemia caused by congenital disorder of glycosylation (CDG) type IIx.

Authors:  P L Calvo; S Pagliardini; M Baldi; A Pucci; L Sturiale; D Garozzo; T Vinciguerra; C Barbera; J Jaeken
Journal:  J Inherit Metab Dis       Date:  2008-12-09       Impact factor: 4.982

5.  On the nomenclature of congenital disorders of glycosylation (CDG).

Authors:  J Jaeken; T Hennet; H H Freeze; G Matthijs
Journal:  J Inherit Metab Dis       Date:  2008-10-24       Impact factor: 4.982

6.  Glycans in evolution and development. Workshop on glycoscience and development.

Authors:  Catherine L R Merry; Sviatlana A Astrautsova
Journal:  EMBO Rep       Date:  2008-06-20       Impact factor: 8.807

Review 7.  Localization of Golgi-resident glycosyltransferases.

Authors:  Linna Tu; David Karl Banfield
Journal:  Cell Mol Life Sci       Date:  2009-09-01       Impact factor: 9.261

Review 8.  Systems glycobiology: biochemical reaction networks regulating glycan structure and function.

Authors:  Sriram Neelamegham; Gang Liu
Journal:  Glycobiology       Date:  2011-03-24       Impact factor: 4.313

9.  Defective mucin-type glycosylation on α-dystroglycan in COG-deficient cells increases its susceptibility to bacterial proteases.

Authors:  Seok-Ho Yu; Peng Zhao; Pradeep K Prabhakar; Tiantian Sun; Aaron Beedle; Geert-Jan Boons; Kelley W Moremen; Lance Wells; Richard Steet
Journal:  J Biol Chem       Date:  2018-07-26       Impact factor: 5.157

10.  Adaptive immune activation: glycosylation does matter.

Authors:  Margreet A Wolfert; Geert-Jan Boons
Journal:  Nat Chem Biol       Date:  2013-12       Impact factor: 15.040

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.